-
I just want to ask, can a medical representative do it for the rest of his life? Multiple MNC questions on behalf of the soul
Time of Update: 2021-01-15
We don't sell anxiety, but the now pharmaceutical industry environment does add to their anxiety. We interviewed 8 first-line medical representatives, some are full of confidence in the future after
-
I just want to ask, can a medical representative do it for the rest of his life? Multiple MNC questions on behalf of the soul
Time of Update: 2021-01-11
Although this medicine represents this position, we all understand that it is an indispensable bridge and link between pharmaceutical companies and doctors, know that "specialization" is a necessary and inevitable future state, but from the current situation to the future of the transformation process, those who have been the status quo has been flattened by the corner of the people who are doing so, is a question that every pharmaceutical person has to think about.
-
At the end of the year, MNC set off a wave of layoffs involving Novartis, Sanofi, Eli Lilly...
Time of Update: 2021-01-02
According to overseas news, Takeda announced on December 21st that it had reached an agreement with Heisman Biopharmaceutical Co., Ltd. to spin off some of its prescription drug business in Chinese ma
-
New drug competition 2.0 era comes AbbVie, Bayer and other MNC and local Biotech group...
Time of Update: 2020-11-15
In particular, the "hug" is mainly between MNC, which has been under pressure in recent years to acquire new growth points, and Biotech, a local company with weak commercialization capabilities for drugs, while others may not have a "new drug shortage" but are frequently attacking the market to expand their research and development pipelines through mergers and acquisitions or licensing deals, a class of drug companies designed to prepare for the storm.
-
The national team's rapid layout MNC heavy gold bet: standing in the air mouth of the medical big data will go where
Time of Update: 2020-11-15
joint venture proposed the name of China Pharmaceutical Intelligent Technology (Shanghai) Co., Ltd., after the establishment of the joint venture, will invest in the construction of a national medical and pharmaceutical emergency protection system Internet platform company.
-
Throw! Innovation "snatching" game opens! Several MNCs have entered the game with pitching.
Time of Update: 2020-10-24
AstraZenecom's first global industrial investment fund has been moving this year as a multinational pharmaceutical industry fund that has re-invested in China's innovative healthcare industry, following Lilly Asia Ventures(LAV).
-
Throw! Innovation "snatching" game opens! Several MNCs have entered the game with pitching.
Time of Update: 2020-10-23
AstraZenecom's first global industrial investment fund has been moving this year as a multinational pharmaceutical industry fund that has re-invested in China's innovative healthcare industry, following Lilly Asia Ventures(LAV).
-
"Pharmaceutical Headline Jun" innovation "snatching" game opened! Several MNCs have entered the game with pitching.
Time of Update: 2020-10-23
(2020/10/12) Following 6 mergers and acquisitions in the first half of the year, 7 more biopharmaceutical companies were acquired in the third quarter; 34 exclusive Chinese medicine terminals sold more than 320 million varieties bucked the trend; and the suspension of insulin to reverse the rare case of type 1 diabetes NEJM indicates the potential of JAK inhibitors...
-
Both products are to be given priority review of how the star biotech/old MNC rides the storm.
Time of Update: 2020-10-15
The Platini capsule, which is to be included in the priority review, was developed by Keystone Pharmaceuticals in cooperation with NASDAQ-listed Blueprint and announced in early July that it had also submitted a listing application for the new drug to the FDA.
-
Domestic anti-cancer new drugs approved for listing increased by 125% YoY, forcing MNC Hengrui, Baiji and other attacks.
Time of Update: 2020-10-08
the second category is from imitation combination to imitation combination, to innovative drug-based bigpharma, to independent research and development of varieties positive PK multinational pharmaceutical companies.
is getting closer to FDA approval time for new drugs in the clinical phase submitted by MNC this year.
-
$21 billion bet! What kind of chess does the MNC play behind its frequent bets?
Time of Update: 2020-10-04
Pfizer's innovative, mature and consumer health businesses are expected to support the "cosmic big drug company", according to its earnings report, but its 2019 results show full-year revenue of $51.8 billion, down 1 percent from a year earlier.
-
Domestic anti-cancer new drugs approved for listing increased by 125% YoY, forcing MNC Hengrui, Baiji and other attacks.
Time of Update: 2020-10-02
the second category is from imitation combination to imitation combination, to innovative drug-based bigpharma, to independent research and development of varieties positive PK multinational pharmaceutical companies.
the sharp leap forward in local pharmaceutical companies, MNC this year's anti-tumor new drugs showed a slight decline due to a variety of factors, such as the outbreak.
-
Domestic anti-cancer new drugs approved for listing increased by 125% YoY, forcing MNC, Hengrui, Baiji hit out head-on!
Time of Update: 2020-10-02
Among them, the local new sharp represented by Baiji Shenzhou with the approval of two new drugs, and Heng Rui Qiping, and Hengrui with the expansion of 2 PD-1 new adaptive disorders, directly forced the K medicine of Merca East, in this innovation battle, the local pharmaceutical companies are ferociously surrounding MNC.
-
The national team's rapid layout MNC heavy gold bet: standing in the air where the big data will go.
Time of Update: 2020-09-27
joint venture proposed the name of China Pharmaceutical Intelligent Technology (Shanghai) Co., Ltd., the joint venture will be established, will invest in the construction of a national medical and pharmaceutical emergency protection system Internet platform company.
-
Where are the hot spots in the field of Amgen preempting the huge layout of MNC such as Johnson and Johnson and Pfizer?
Time of Update: 2020-09-05
years, the pace of domestic pharmaceutical companies to explore the application of lysovirus and tumor immuno combination therapy is also accelerating.
with the domestic tumor immuno-checkpoint inhibitors approved for market, Ankeri is expected to become one of the important options for PD-1 and PD-L1 drugs.